Methods of treating alpha adrenergic mediated conditions

Abstract

Described herein are compounds for and methods of treating conditions or diseases in a subject by administering to the subject a pharmaceutical composition containing an effective amount of an α-adrenergic modulator. The compounds and methods are also useful for alleviating types of pain, acute, neuropathic and chronic.

What is claimed is: 
     
         1 . A method of treating a condition or disease alleviated by activation of α-adrenergic receptors in a mammal, the method comprising administering to the mammal in need of such treatment a pharmaceutically effective dose of N-(2,3-dichlorobenzyl)-4,5-dihydro-1H-imidazol-2-amine having the following structure: 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof. 
       
     
     
         2 . The method of  claim 1 , wherein the condition or disease is selected from the group consisting of hypertension, congestive heart failure, asthma, depression, glaucoma, elevated intraocular pressure, ischemic neuropathies, optic neuropathy, pain, visceral pain, corneal pain, headache pain, migraine, cancer pain, back pain, irritable bowel syndrome pain, muscle pain, pain associated with diabetic neuropathy, the treatment of diabetic retinopathy, other retinal degenerative conditions, stroke, cognitive deficits, neuropsychiatric conditions, drug dependence, drug addiction, withdrawal symptoms, obsessive compulsive disorder, obesity, insulin resistance, stress related conditions, diarrhea, diuresis, nasal congestions, spasticity, attention deficit disorder, psychoses, anxiety, autoimmune disease, Crohn's disease, gastritis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and other neurodegenerative diseases. 
     
     
         3 . The method of  claim 1 , wherein the dose is administered by an oral route. 
     
     
         4 . The method of  claim 3 , wherein the dose is orally administered in the form of a tablet, liquid, capsule or powder. 
     
     
         5 . The method of  claim 1 , wherein the dose is administered by a transdermal, parenteral, subcutaneous, intranasal, intrathecal, intramuscular, intravenous or intrarectal route. 
     
     
         6 . The method of  claim 1 , wherein the mammal is a human. 
     
     
         7 . A pharmaceutical composition comprising a compound having the structure: 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt or imine tautomer thereof.